共 56 条
[1]
Shimamoto K(2014)The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2014) Hypertens Res 37 253-390
[2]
Ando K(2003)Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure Hypertension 42 1206-1252
[3]
Fujita T(2006)Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients J Clin Hypertens (Greenwich) 8 634-641
[4]
Chobanian AV(2013)2013 ESH/ESC guidelines for the management of arterial hypertension Eur Heart J 34 2159-2219
[5]
Bakris GL(2015)The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies Am J Hypertens 28 1376-1385
[6]
Black HR(2015)Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial Lancet 386 2059-2068
[7]
Tedesco MA(2012)Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension Am J Hypertens 25 514-523
[8]
Natale F(2016)Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016 Am J Med 129 661-666
[9]
Calabro R(2016)Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis J Hum Hypertens 30 534-542
[10]
Mancia G(2016)New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension Curr Hypertens Rep 18 34-273